DE69535734D1 - Therapeutische Zusammensetzungen von Venösdilatoren und Arterielldilatoren - Google Patents

Therapeutische Zusammensetzungen von Venösdilatoren und Arterielldilatoren

Info

Publication number
DE69535734D1
DE69535734D1 DE69535734T DE69535734T DE69535734D1 DE 69535734 D1 DE69535734 D1 DE 69535734D1 DE 69535734 T DE69535734 T DE 69535734T DE 69535734 T DE69535734 T DE 69535734T DE 69535734 D1 DE69535734 D1 DE 69535734D1
Authority
DE
Germany
Prior art keywords
dilators
venous
arterial
therapeutic compositions
vasoconstriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535734T
Other languages
English (en)
Inventor
Wayne H Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogenix Inc
Original Assignee
Angiogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenix Inc filed Critical Angiogenix Inc
Application granted granted Critical
Publication of DE69535734D1 publication Critical patent/DE69535734D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69535734T 1994-10-05 1995-10-05 Therapeutische Zusammensetzungen von Venösdilatoren und Arterielldilatoren Expired - Lifetime DE69535734D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/321,051 US5543430A (en) 1994-10-05 1994-10-05 Method and formulation of stimulating nitric oxide synthesis

Publications (1)

Publication Number Publication Date
DE69535734D1 true DE69535734D1 (de) 2008-04-24

Family

ID=23248976

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69533940T Expired - Lifetime DE69533940T2 (de) 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE69535734T Expired - Lifetime DE69535734D1 (de) 1994-10-05 1995-10-05 Therapeutische Zusammensetzungen von Venösdilatoren und Arterielldilatoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69533940T Expired - Lifetime DE69533940T2 (de) 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren

Country Status (12)

Country Link
US (2) US5543430A (de)
EP (2) EP0784429B1 (de)
JP (1) JPH10507443A (de)
AT (2) ATE287212T1 (de)
AU (1) AU705002B2 (de)
CA (1) CA2201784C (de)
DE (2) DE69533940T2 (de)
DK (1) DK0784429T3 (de)
ES (1) ES2236716T3 (de)
MX (1) MX9702527A (de)
PT (1) PT784429E (de)
WO (1) WO1996010910A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945452A (en) * 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
US6911427B1 (en) * 1995-09-15 2005-06-28 Duke University No-modified hemoglobins and uses therefore
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US6297273B1 (en) 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US7968140B2 (en) * 1997-09-08 2011-06-28 Mars, Incorporated Chocolates and chocolate liquor having an enhanced polyphenol content
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6436996B1 (en) 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
JP2001519386A (ja) * 1997-10-15 2001-10-23 トーマス・ジェファーソン・ユニバーシティ 哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US6805883B2 (en) 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
US8507018B2 (en) 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
EP1150669A4 (de) * 1999-02-05 2005-06-22 Angiogenix Inc Formulierungen auf l-argininbasis zur krankheitsbehandlung und deren verwendungsmethoden
EP1175210A4 (de) * 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc Verbesserung der bioverfügbarkeit von arzneimitteln im hirn
US6162237A (en) * 1999-04-19 2000-12-19 Chan; Winston Kam Yew Temporary intravascular stent for use in retrohepatic IVC or hepatic vein injury
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
IL141250A0 (en) * 1999-06-05 2002-03-10 Univ Leland Stanford Junior Method and composition for inhibiting cardiovascular cell proliferation
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
WO2001078717A1 (en) 2000-04-12 2001-10-25 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6284790B1 (en) 2000-06-15 2001-09-04 Sachin Gupte Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
CA2414941C (en) 2000-08-11 2010-12-14 David R. Whitlock Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US20030228564A1 (en) * 2001-05-30 2003-12-11 Edrich Richard Alan Nitric oxide in a pathogen inactivation process
JP2005515218A (ja) * 2002-01-11 2005-05-26 ホイットロック，デービッド，アール． アンモニア酸化細菌を含む組成物およびその使用方法
US7079888B2 (en) * 2002-04-11 2006-07-18 Ansar, Inc. Method and apparatus for monitoring the autonomic nervous system using non-stationary spectral analysis of heart rate and respiratory activity
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
KR20050083827A (ko) * 2002-10-24 2005-08-26 이노스 파마슈티칼스, 인코포레이티드 서방성 ｌ-아르기닌 포뮬레이션 및 이의 제조방법 및 용도
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
WO2004071437A2 (en) * 2003-02-07 2004-08-26 Barmensen, Inc. Compositions for enhancing sexual responsiveness
US20040254238A1 (en) * 2003-04-07 2004-12-16 Osteoscreen Bone growth stimulation with NO/statin and other NO modulating combinations
AU2004275868A1 (en) * 2003-09-26 2005-04-07 David R. Whitlock Methods of using ammonia oxidizing bacteria
EP1675619A4 (de) * 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc L-arginin-formulierungen mit verzögerter freisetzung und herstellungs- und verwendungsverfahren dafür
US20050095196A1 (en) * 2003-10-29 2005-05-05 Black Keith L. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
EP1732577B1 (de) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topische verabreichung von l-arginin zur verbesserung des aussehens von körper und haut
WO2005084301A2 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
CA2563678A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
US7731993B2 (en) * 2004-11-17 2010-06-08 Lindsey Berkson Composition for treating a dermal anomaly
BRPI0517731A (pt) * 2004-11-17 2008-10-21 Lindsey Berkson composição e método para facilitar a cicatrização de ferimentos e ulcerações que não cicatrizam e de cicatrização lenta
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
US10646508B1 (en) 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US8569369B2 (en) 2007-09-18 2013-10-29 Thermolife International, Llc Amino acid compounds
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
JP5623916B2 (ja) * 2008-01-31 2014-11-12 バンダービルト・ユニバーシティＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物
TR201903753T4 (tr) * 2008-01-31 2019-03-21 Univ Vanderbilt Akciğer rahatsızlıkları için terapötik tedavi.
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445492B1 (de) 2009-06-24 2016-09-28 Strategic Science & Technologies, LLC Topische zusammensetzung mit ibuprofen
EP2658551B1 (de) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Behandlung von erektionsstörungen und anderen indikationen
CN105878172A (zh) 2010-12-29 2016-08-24 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
US8936635B2 (en) 2011-03-23 2015-01-20 Palmetto Pharmaceuticals Llc Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents
AU2012242565B2 (en) 2011-04-13 2017-05-11 Thermolife International, Llc N-Acetyl Beta Alanine methods of use
CN111057660B (zh) 2014-04-15 2023-10-31 Ao生物医学有限责任公司 氨氧化型亚硝化单胞菌菌株d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5059712A (en) * 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
US5273875A (en) * 1991-03-22 1993-12-28 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5132453A (en) * 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5132407A (en) * 1991-09-26 1992-07-21 Cornell Research Foundation, Inc. Purified inducible nitric oxide synthase flavoprotein
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
US5281627A (en) * 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof

Also Published As

Publication number Publication date
DK0784429T3 (da) 2005-05-23
EP0784429A1 (de) 1997-07-23
EP0784429B1 (de) 2005-01-19
ATE388700T1 (de) 2008-03-15
JPH10507443A (ja) 1998-07-21
EP1552745B1 (de) 2008-03-12
DE69533940D1 (de) 2005-02-24
US5767160A (en) 1998-06-16
DE69533940T2 (de) 2005-12-22
EP0784429A4 (de) 2001-02-07
PT784429E (pt) 2005-05-31
ATE287212T1 (de) 2005-02-15
CA2201784A1 (en) 1996-04-18
US5543430A (en) 1996-08-06
CA2201784C (en) 2004-08-24
EP1552745A1 (de) 2005-07-13
AU705002B2 (en) 1999-05-13
MX9702527A (es) 1998-02-28
ES2236716T3 (es) 2005-07-16
AU3889695A (en) 1996-05-02
WO1996010910A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
ATE388700T1 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE68902649T2 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE3485581D1 (de) Antioestrogenes arzneimittel zur perkutanen verabreichung.
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
NO920395L (no) Terapeutisk aktive benzyloksyfenyl-derivater og fremgangsmaate for deres fremstilling
KR880007070A (ko) 백내장 치료용 약학 조성물
RU94042230A (ru) Производные 1,3,4-оксадиазол-2-(3н)-она, их приготовление и применение в терапии
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
RU2003118131A (ru) Способ лечения ран
RU2177307C1 (ru) Лечебно-косметическое средство
NL7513892A (en) Ascorbic acid medicaments for external use - as nasal decongestants and to promote resistance to infection
KR880000094A (ko) 위염치료제
RU94042022A (ru) Лекарственное средство для лечения ишемии мозга
KR890001555A (ko) 요산 배설용 조성물
Turnbull Study of one hundred and twenty-seven cases of arthritis (with notes on gastro-intestinal features)
RU94004116A (ru) Способ лечения розовых угрей
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии
KR890001549A (ko) 위염 치료제
RU93053982A (ru) Мазь для лечения открытых ран

Legal Events

Date Code Title Description
8332 No legal effect for de